{"id":67190,"date":"2026-06-03T14:33:13","date_gmt":"2026-06-03T06:33:13","guid":{"rendered":"https:\/\/flcube.com\/?p=67190"},"modified":"2026-06-03T14:33:14","modified_gmt":"2026-06-03T06:33:14","slug":"abbvies-aquipta-atogepant-receives-european-commission-approval-for-acute-migraine-treatment-expanding-beyond-preventive-use","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67190","title":{"rendered":"AbbVie’s AQUIPTA (Atogepant) Receives European Commission Approval for Acute Migraine Treatment, Expanding Beyond Preventive Use"},"content":{"rendered":"\n

AbbVie Inc.<\/strong> (NYSE: ABBV<\/a>) announced that the European Commission (EC)<\/strong> has granted marketing authorization for AQUIPTA (atogepant)<\/strong> as an acute treatment for migraine in adults<\/strong>, complementing its existing approval as a preventive therapy<\/strong> for chronic and episodic migraine.<\/p>\n\n\n\n

This dual-label approval positions atogepant as the first oral CGRP receptor antagonist (gepant)<\/strong> in Europe approved for both preventive and acute migraine treatment<\/strong>, offering physicians and patients unprecedented flexibility in managing this debilitating neurological condition affecting over 50 million Europeans.<\/p>\n\n\n\n

Regulatory Milestone & Indication Expansion<\/h2>\n\n\n\n
Parameter<\/th>Detail<\/th><\/tr><\/thead>
Regulatory Authority<\/strong><\/td>European Commission (EC)<\/td><\/tr>
Approval Date<\/strong><\/td>June 2, 2026<\/td><\/tr>
Product Name<\/strong><\/td>AQUIPTA (atogepant)<\/td><\/tr>
New Indication<\/strong><\/td>Acute treatment of migraine with or without aura (as needed\/PRN)<\/td><\/tr>
Existing Indication<\/strong><\/td>Preventive treatment for chronic\/episodic migraine (\u22654 migraine days\/month)<\/td><\/tr>
Drug Class<\/strong><\/td>Oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant)<\/td><\/tr>
Dosage Form<\/strong><\/td>Oral tablet<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Phase 3 ECLIPSE Study Results<\/h2>\n\n\n\n
Endpoint<\/th>Atogepant (60 mg)<\/th>Placebo<\/th>Statistical Significance<\/th><\/tr><\/thead>
Primary Endpoint: Pain Freedom at 2 Hours<\/strong><\/td>Superior efficacy<\/td>Reference<\/td>p<0.0001<\/td><\/tr>
Study Design<\/strong><\/td>Single attack treatment + multiple attack consistency<\/td>\u2013<\/td>Met primary endpoint<\/td><\/tr>
Patient Population<\/strong><\/td>Adults with migraine history (with\/without aura)<\/td>\u2013<\/td>Broad applicability<\/td><\/tr>
Treatment Paradigm<\/strong><\/td>As-needed (PRN) dosing<\/td>\u2013<\/td>Flexible patient use<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Dual-Use Therapeutic Strategy<\/h2>\n\n\n\n